References
- National Institute for Clinical Excellence. Technology Appraisal Guidance No.7: Guidance on the use of proton pump inhibitors in the treatment of dyspepsia. National Institute for Clinical Excellence, 2000.
- Revicki DA, Wood M, Maton PN et al. The impact of gastroesophageal reflux disease on health-related quality of life. American Journal of Medicine 1998; 104: 252–258.
- Henke CJ, Levin TR, Henning JM et al. Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a Health Maintenance Organization. American Journal of Gastroenterology 2000; 95: 788–792.
- Wahlqvist P. Symptoms of gastroesophageal reflux disease, perceived productivity, and health-related quality of life. American Journal of Gastroenterology 2001; 96 (Suppl. 8): S57–61.
- Moayyedi P, Delaney B, Katzka D et al. Gastro-oesophageal reflux disease. Clinical Evidence 2000; 5: 311–323.
- Moore RA, Phillips C. Reflux oesophagitis: quantitative systematic review of evidence of effectiveness of proton pump inhibitors and histamine antagonists. Bandolier, 1999.
- Chiba N, de Gara CJ, Wilkinson JM et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 122: 1798–1810.
- Sharma VK, Leontiadis GI, Howden CW. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Alimentary Pharmacology and Therapeutics 2001; 15: 227–231.
- Lind T, Rydberg L, Kylebäck A et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics 2000; 14: 861–867.
- Röhss K, Wilder-Smith C, Claar-Nilsson C et al. Esomeprazole 40mg provides more effective acid control than standard doses of all other proton pump inhibitors. Gastroenterology 2001; 120: A419.
- Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Alimentary Pharmacology and Therapeutics 2001; 15: 1729–1736.
- Clarke M, Oxman AD (Eds). Cochrane Reviewer’s Handbook 4.0. Oxford: The Cochrane Collaboration, 1999.
- British National Formulary 42. London: British Medical Association and the British Pharmaceutical Society of Great Britain, September 2001.
- Bate CM, Richardson PDI. Cost- effectiveness of omeprazole in the management of gastroesophageal reflux disease in clinical practice. British Journal of Medical Economics 1994; 7: 81–97.
- Netten A, Curtis L. Unit costs of health and social care 2000. University of Kent Canterbury: PSSRU, 2000.
- Chartered Institute of Public Finance & Accountancy (CIPFA): Health Database 2000, London.
- Wahlqvist P, Higgins A, Green J. Management of GORD in the UK — results of a survey. European Journal of Internal Medicine 2001; 12: A273–A274.
- Castell DO, Kahrilas PJ, Richter JE et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive oesophagitis. American Journal of Gastroenterology 2002; 97: 575–583.
- Lauritsen K et al. Esomeprazole 20 mg compared with lansoprazole 15 mg in patients with healed reflux oesophagitis. Abstract presented at the 12th World Congress of Gastroenterlogy 24th Feb – 1st March 2002.